Orphenadrine (Monograph)
Drug class:
VA class: MS200
Introduction
Centrally acting skeletal muscle relaxant.110 120 121 122 125
Uses for Orphenadrine
Muscular Conditions
Used alone or in combination with aspirin and caffeine as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.120 121 122
If pharmacologic therapy is required for acute low back pain (usually a benign and self-limiting condition105 106 108 ), experts state that an NSAIA or skeletal muscle relaxant may be considered.109 Skeletal muscle relaxants may provide small improvements in pain relief, but are associated with a high incidence of adverse effects (e.g., CNS effects).104 106 107 108 109 Use with caution after weighing risks against benefits.104 106 107 108
Various skeletal muscle relaxants appear to have comparable efficacy for low back pain relief.103 104 106 108
Orphenadrine Dosage and Administration
Administration
Administer orally or by IV or IM injection.120 121 122
Oral Administration
Administer extended-release tablets orally twice daily (once in the morning and once in the evening).120
Administer fixed-combination tablets (with aspirin and caffeine) orally 3 or 4 times daily.122
IV Administration
Place patient in supine position during and for 5–10 minutes following IV injection.a (See CNS Effects under Cautions.) To minimize adverse reactions, assist patient from recumbent position after the drug is administered.a
Rate of Administration
Administer IV over about 5 minutes.a
Dosage
Available as orphenadrine citrate; dosage expressed in terms of the salt.120 121 122
Adults
Muscular Conditions
Extended-release Tablets
Oral100 mg twice daily.120
Fixed-combination Tablets
Oral25–50 mg (in combination with aspirin 385–770 mg and caffeine 30–60 mg) 3 or 4 times daily.122
Parenteral Therapy
IV or IM60 mg every 12 hours.121
Cautions for Orphenadrine
Contraindications
-
Prostatic hypertrophy or obstruction of the bladder neck.120 121
-
Known hypersensitivity to orphenadrine or any ingredient in the formulation.120 121
Warnings/Precautions
Warnings
CNS Effects
Transient episodes of lightheadedness, dizziness, or syncope reported.120 121
Performance of activities requiring mental alertness or physical coordination (e.g., operating machinery, driving a motor vehicle) may be impaired.120 121
Sensitivity Reactions
Sulfite Sensitivity
Injectable formulation contains sodium bisulfite, which can cause allergic-type reactions, including anaphylaxis and life-threatening or less severe asthmatic episodes, in certain susceptible individuals.100 121
Overall prevalence of sulfite sensitivity in the general population unknown but probably low; such sensitivity appears to occur more frequently in asthmatic than in nonasthmatic individuals.100 121
General Precautions
Adequate Patient Monitoring
Safety of continuous therapy not established.120 121 Perform periodic blood, urine, and liver function tests during prolonged orphenadrine therapy120 121
Cardiac Effects
Possible tachycardia and palpitation; may be associated with increased dosages.120 121 Use with caution in patients with tachycardia, cardiac decompensation, coronary insufficiency, or cardiac arrhythmias.120 121
Use of Fixed Combinations
When orphenadrine is used in fixed combination with aspirin and caffeine, consider the cautions, precautions, and contraindications associated with each agent in the combination.122
Specific Populations
Pregnancy
Category C.120
Not known whether the drug can cause fetal harm or affect reproductive capacity.120 121 Use during pregnancy only if potential benefits outweigh potential risks, particularly during early pregnancy.120 121
Lactation
Not known whether orphenadrine is distributed into milk; use with caution.a
Pediatric Use
Safety and efficacy not established.120 121
Geriatric Use
Because of risk of injury, skeletal muscle relaxants should generally be avoided in geriatric patients.111
Common Adverse Effects
Dry mouth, tachycardia, palpitation, urinary hesitancy or retention, blurred vision, dilatation of pupils, increased intraocular pressure, weakness, nausea, vomiting, headache, dizziness, constipation, drowsiness.120 121
Orphenadrine Pharmacokinetics
Absorption
Bioavailability
Readily absorbed following oral administration.a
Distribution
Extent
Distribution not fully characterized in humans.a In animals, detected in all organs, especially those with greatest perfusion (e.g., lungs).a
Orphenadrine may cross the placenta; not known whether distributed into milk.a
Elimination
Metabolism
Almost completely metabolized to at least 8 metabolites; however, metabolic fate not fully determined.a
Elimination Route
Eliminated principally in urine as metabolites and, in small amounts, as unchanged drug.a
Half-life
Approximately 14 hours.a
Stability
Storage
Oral
Tablets
20–25°C in tight, light-resistant containers.120
Parenteral
Injection
20–25°C.121 Protect from light; do not use if precipitation occurs.121
Actions
-
Centrally acting skeletal muscle relaxant.110 120 121 122 125
-
Precise mechanism of action not known.120 121 Does not directly relax skeletal muscle;120 121 therapeutic action may be related to analgesic properties.120 121
-
May reduce skeletal muscle spasm, possibly through an atropine-like central action on cerebral motor centers or on the medulla.a
-
Exhibits postganglionic anticholinergic, antihistaminic, and local anesthetic properties.a
Advice to Patients
-
Potential to impair mental alertness or physical coordination; use caution when driving or operating machinery until effects on individual are known.120 121
-
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as concomitant illnesses.120 121
-
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.120 121
-
Importance of informing patients of other important precautionary information.120 121 (See Cautions.)
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
---|---|---|---|---|
Oral |
Tablets, extended-release |
100 mg* |
Orphenadrine Citrate Extended-release Tablets |
|
Parenteral |
Injection |
30 mg/mL* |
Orphenadrine Citrate Injection |
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
---|---|---|---|---|
Oral |
Tablets |
25 mg with Aspirin 385 mg and Caffeine 30 mg* |
Orphenadrine Citrate, Aspirin, and Caffeine Tablets |
|
50 mg with Aspirin 770 mg and Caffeine 60 mg* |
Orphenadrine Citrate, Aspirin, and Caffeine Tablets |
|||
Orphengesic Forte |
Galt |
AHFS DI Essentials™. © Copyright 2024, Selected Revisions March 10, 2024. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
References
Only references cited for selected revisions after 1984 are available electronically.
100. Food and Drug Administration. Sulfiting agents; labeling in drugs for human use; warning statements. [21 CFR Part 201] Fed Regist. 1986; 51:43900-5.
103. See S, Ginzburg R. Skeletal muscle relaxants. Pharmacotherapy. 2008; 28:207-13. http://www.ncbi.nlm.nih.gov/pubmed/18225966?dopt=AbstractPlus
104. van Tulder MW, Touray T, Furlan AD et al. Muscle relaxants for non-specific low back pain. Cochrane Database Syst Rev. 2003; :CD004252. http://www.ncbi.nlm.nih.gov/pubmed/12804507?dopt=AbstractPlus
105. Roelofs PD, Deyo RA, Koes BW et al. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev. 2008; :CD000396. http://www.ncbi.nlm.nih.gov/pubmed/18253976?dopt=AbstractPlus
106. Chou R, Qaseem A, Snow V et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med. 2007; 147:478-91. http://www.ncbi.nlm.nih.gov/pubmed/17909209?dopt=AbstractPlus
107. Institute for Clinical Systems Improvement. Health care guideline: adult acute and subacute low back pain. 15th ed. Bloomington, MN; 2012 Jan. From the ICSI website http://www.icsi.org/low_back_pain/adult_low_back_pain__8.html
108. Toth PP, Urtis J. Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clin Ther. 2004; 26:1355-67. http://www.ncbi.nlm.nih.gov/pubmed/15530999?dopt=AbstractPlus
109. Qaseem A, Wilt TJ, McLean RM et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017; 166:514-530. http://www.ncbi.nlm.nih.gov/pubmed/28192789?dopt=AbstractPlus
110. Friedman BW, Cisewski D, Irizarry E et al. A Randomized, Double-Blind, Placebo-Controlled Trial of Naproxen With or Without Orphenadrine or Methocarbamol for Acute Low Back Pain. Ann Emerg Med. 2018; 71:348-356.e5. http://www.ncbi.nlm.nih.gov/pubmed/29089169?dopt=AbstractPlus
111. Spence MM, Shin PJ, Lee EA et al. Risk of injury associated with skeletal muscle relaxant use in older adults. Ann Pharmacother. 2013 Jul-Aug; 47:993-8. http://www.ncbi.nlm.nih.gov/pubmed/23821610?dopt=AbstractPlus
112. Friedman BW, Irizarry E, Solorzano C et al. A Randomized, Placebo-Controlled Trial of Ibuprofen Plus Metaxalone, Tizanidine, or Baclofen for Acute Low Back Pain. Ann Emerg Med. 2019; http://www.ncbi.nlm.nih.gov/pubmed/30955985?dopt=AbstractPlus
113. Friedman BW, Dym AA, Davitt M et al. Naproxen With Cyclobenzaprine, Oxycodone/Acetaminophen, or Placebo for Treating Acute Low Back Pain: A Randomized Clinical Trial. JAMA. 2015; 314:1572-80. http://www.ncbi.nlm.nih.gov/pubmed/26501533?dopt=AbstractPlus
120. Sandoz. Orphenadrine citrate extended-release tablets prescribing information. Princeton, NJ: 2017 July.
121. Actavis. Orphenadrine citrate injection prescribing information. Parsiappy, NJ: 2016 July.
122. Galt. Orphengesic Forte (orphenadrine citrate, aspirin, and caffeine tablets 50 mg/770 mg/60 mg) prescribing information. Atlanta, GA: 2018 Sept.
123. Katzenschlager R, Sampaio C, Costa J et al. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev. 2003; :CD003735. http://www.ncbi.nlm.nih.gov/pubmed/12804486?dopt=AbstractPlus
124. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014 Apr 23-30; 311:1670-83. http://www.ncbi.nlm.nih.gov/pubmed/24756517?dopt=AbstractPlus
125. Hunskaar S, Donnell D. Clinical and pharmacological review of the efficacy of orphenadrine and its combination with paracetamol in painful conditions. J Int Med Res 1991 Mar-Apr;19(2):71-87.
a. AHFS Drug Information 2020. Snow EK, ed. Metaxalone. Bethesda, MD: American Society of Health-System Pharmacists; 2020.
More about orphenadrine
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (82)
- Drug images
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- Drug class: skeletal muscle relaxants
- Breastfeeding
- En español